Please wait while the transcript is being prepared...
0:00
Hello. I'm Giovanni Tosi.
I'm an Associate Professor at
the University of Modena and Reggio Emilia in the field of Pharmaceutical Sciences.
I'm belonging to the Parliament of Life Science and my work is mainly devoted
to nanomedicine and in particular to the application of nanomedicine in brain disease.
0:20
So, if you look at the last 10 years of nanomedicine for brain disease records,
you will see that a very huge number of papers published in
different international journals with
skilled preclinical results mainly on therapeutics and diagnostics.
0:37
But, if you go to look how many are the nanomedicine products for brain disease markets,
you will find absolutely nothing.
So, it is the Death Valley of this nanomedicine approach.
0:52
So, there are many factors that will affect the marketability of
nanomedicine for brain disease on marketing that are mainly dealing with safety,
efficacy, GMP production, scaling up of nanomedicine,
and there's a problem in economics sustainability.
So, the question now is if the problem is connected with nanomedicine
as nano-sized systems or the problem is connected with the targets that is the brain.
1:20
So, in my talk,
I will try to go depth into some question and
some take-home message that we can take off from our research
in dealing with the blood-brain barrier which is the first topic and
then going into topics like planning a nano-4-neuro,
strategies for blood-brain barrier crossing,
and some technological and pharmacological issue.
Finish with some experience that has in this field.
So, the first topic is the blood-brain barrier.
